This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Y's Therapeutics, Inc.
Drug Names(s): r-PSGL-Ig, recombinant P-selectin glycoprotein immunoglobulin
Description: YSPSL is a recombinant molecule resulting from the fusion of P-selectin glycoprotein ligand (PSGL) and human IgG1.
YSPSL blocks a class of adhesion molecules known as selectins and prevents the accumulation of both leukocytes and platelets at sites of inflammation. Specifically, it binds to selectins expressed on activated platelets and endothelial cells. Consequently, YSPSL inhibits binding of inflammatory cells bearing selectin ligands as well as subsequent inflammatory activity, platelet coagulation and thrombosis. Administration of YSPSL in animal models of transplantation suggests it may also upregulate anti-apoptotic genes such as hemoxygenase-1 that protect organs from ischemia-reperfusion injury.
Deal Structure: YSPSL was developed by Wyeth and was acquired by Ys Therapeutics from an undisclosed California biotechnology company in June 2005, providing Ys with an exclusive, worldwide license from Wyeth for development and commercialization.
In January 2009, Pfizer and Wyeth announced that they entered into a definitive merger agreement under which Pfizer will acquire Wyeth in a cash-and-stock transaction currently valued at $50.19 per share, or a total of approximately $68 billion. The acquisition was completed in October 2009.
Partners: Pfizer Inc.
Additional information available to subscribers only: